We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Potassium wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
10 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both MitoQ and Potassium have evidence — compare verdict strength side-by-side.
10-20mg daily
morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
99-500mg daily from supplements (food provides more)
With food to reduce GI upset, Spread throughout day, During/after exercise for athletes
Potassium Citrate or Potassium Gluconate
Acute to 6 weeks
4 weeks
12 months
3 weeks
2-4 weeks
1-2 weeks
Long-term
With excess or kidney issues
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
Effect of changes in potassium intake on blood pressure: a dose–response meta-analysis of randomized clinical trials (2000–2024)
Clinical Kidney Journal (2025) · Meta analysis · n=2500
Dose-response analysis of RCTs from 2000-2024
Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length
Nutrients (2024) · Meta analysis
Both supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations.
Sex-specific associations between sodium and potassium intake and overall and cause-specific mortality: a large prospective U.S. cohort study, systematic review, and updated meta-analysis of cohort studies
BMC medicine (2024) · Meta analysis · n=237036
Meta-analysis examining Potassium efficacy
Potassium has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.
For reduce inflammation, Potassium has a higher relevance score (85 vs 45).
No known interactions between MitoQ and Potassium have been documented in our database. However, always consult a healthcare provider before combining supplements.